Generation Bio Co.

NasdaqGS GBIO

Generation Bio Co. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 18.58 M

Generation Bio Co. Revenue is USD 18.58 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 514.08% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Generation Bio Co. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 3.03 M, a 0.00% change year over year.
Generation Bio Co. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
Generation Bio Co. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00, a 0.00% change year over year.
Generation Bio Co. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqGS: GBIO

Generation Bio Co.

CEO	Dr. Cameron Geoffrey McDonough M.D.
IPO Date	June 12, 2020
Location	United States
Headquarters	301 Binney Street
Employees	174
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years